📊 CHRS Key Takeaways
Is Coherus Oncology, Inc. (CHRS) a Good Investment?
Coherus Oncology is a pre-commercial or early-stage biotech company burning significant cash ($57.9M operating, $58.2M free cash flow) with minimal revenue generation ($12.3M) and no path to profitability visible. While 59.8% revenue growth and a $115.2M cash position provide near-term runway (~2 years), the company faces severe unit economics with negative operating margins (-293.7%) that require fundamental business model improvement or successful product commercialization to avoid dilutive financing.
Coherus Oncology shows strong top-line growth, but the core business remains deeply unprofitable, with a -429.5% operating margin and large negative free cash flow. Reported net income appears low quality because it is inconsistent with operating losses and cash burn, suggesting non-recurring or non-operating items are driving earnings rather than durable operating improvement. Liquidity is still adequate near term, but leverage and ongoing cash consumption create meaningful financial risk if revenue growth does not translate into sustainable operating cash flow.
Coherus Oncology, Inc. Key Strengths (CHRS)
- Strong absolute cash position of $115.2M provides operational runway
- Revenue growth of 59.8% YoY demonstrates some market traction and commercial progress
- Reasonable short-term liquidity (1.56x current ratio, 1.52x quick ratio) and moderate leverage (0.94x debt-to-equity)
- Revenue grew 59.8% year over year, indicating improving commercial traction
- Cash and equivalents of $88.88M and current ratio of 1.47x provide some near-term liquidity support
- Low capital expenditure requirements reduce the burden of maintaining the asset base
CHRS Stock Risks: Coherus Oncology, Inc. Investment Risks
- Severe cash burn of $57.9M annually with negative FCF limits runway to approximately 2 years at current burn rate
- Operating losses of $36.2M and net losses of $38.3M indicate company cannot support expenses from revenue; no profitability visibility
- Data quality concerns (942.7% gross margin with $12.3M revenue generating $116.1M gross profit) suggest potential accounting or reporting issues that undermine financial statement reliability
- Negative interest coverage (-16.5x) and significant debt ($73.7M) create refinancing risk if cash depletes
- Core operations remain severely unprofitable, with operating income of -$181.13M and negative interest coverage
- Operating cash flow of -$138.51M and free cash flow of -$138.80M indicate substantial ongoing cash burn
- Debt-to-equity of 1.21x and a small equity base increase balance-sheet risk if losses persist
Key Metrics to Watch
- Quarterly revenue growth trajectory and whether 59.8% growth rate accelerates or decelerates
- Operating cash flow burn rate and runway extension through cost controls or revenue inflection
- Achievement of clinical/commercialization milestones that could improve unit economics and reduce cash burn
- Operating cash flow and quarterly cash burn trend
- Whether revenue growth converts into materially improved operating margin
Coherus Oncology, Inc. (CHRS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Coherus Oncology, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
CHRS Profit Margin, ROE & Profitability Analysis
CHRS vs Healthcare Sector: How Coherus Oncology, Inc. Compares
How Coherus Oncology, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Coherus Oncology, Inc. Stock Overvalued? CHRS Valuation Analysis 2026
Based on fundamental analysis, Coherus Oncology, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Coherus Oncology, Inc. Balance Sheet: CHRS Debt, Cash & Liquidity
CHRS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Coherus Oncology, Inc.'s revenue has declined by 91% over the 5-year period, indicating business contraction. The most recent EPS of $0.25 reflects profitable operations.
CHRS Revenue Growth, EPS Growth & YoY Performance
CHRS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $7.6M | -$38.3M | $-0.28 |
| Q3 2025 | $6.1M | -$10.8M | $-0.09 |
| Q2 2025 | $10.3M | -$12.9M | $-0.11 |
| Q1 2025 | $2.3M | -$56.6M | $-0.49 |
| Q3 2024 | $70.8M | -$10.8M | $-0.09 |
| Q2 2024 | $58.7M | -$12.9M | $-0.11 |
| Q1 2024 | $32.4M | -$75.7M | $0.83 |
| Q3 2023 | $45.4M | -$39.6M | $-0.41 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Coherus Oncology, Inc. Dividends, Buybacks & Capital Allocation
CHRS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Coherus Oncology, Inc. (CIK: 0001512762)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CHRS
What is the AI rating for CHRS?
Coherus Oncology, Inc. (CHRS) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 75% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CHRS's key strengths?
Claude: Strong absolute cash position of $115.2M provides operational runway. Revenue growth of 59.8% YoY demonstrates some market traction and commercial progress. ChatGPT: Revenue grew 59.8% year over year, indicating improving commercial traction. Cash and equivalents of $88.88M and current ratio of 1.47x provide some near-term liquidity support.
What are the risks of investing in CHRS?
Claude: Severe cash burn of $57.9M annually with negative FCF limits runway to approximately 2 years at current burn rate. Operating losses of $36.2M and net losses of $38.3M indicate company cannot support expenses from revenue; no profitability visibility. ChatGPT: Core operations remain severely unprofitable, with operating income of -$181.13M and negative interest coverage. Operating cash flow of -$138.51M and free cash flow of -$138.80M indicate substantial ongoing cash burn.
What is CHRS's revenue and growth?
Coherus Oncology, Inc. reported revenue of $12.3M.
Does CHRS pay dividends?
Coherus Oncology, Inc. does not currently pay dividends.
Where can I find CHRS SEC filings?
Official SEC filings for Coherus Oncology, Inc. (CIK: 0001512762) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CHRS's EPS?
Coherus Oncology, Inc. has a diluted EPS of $-0.28.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CHRS's fundamental grade?
Based on our AI fundamental analysis in June 2026, Coherus Oncology, Inc. has a C grade with 75% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CHRS stock overvalued or undervalued?
Valuation metrics for CHRS: ROE of -48.7% (sector avg: 15%), net margin of -311.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CHRS's AI grade for 2026?
Our dual AI analysis gives Coherus Oncology, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CHRS's free cash flow?
Coherus Oncology, Inc.'s operating cash flow is $-57.9M, with capital expenditures of $286.0K. FCF margin is -472.6%.
How does CHRS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -311.3% (avg: 12%), ROE -48.7% (avg: 15%), current ratio 1.56 (avg: 2).